Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Disseminated cryptococcosis? 16 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Disseminated cryptococcosis have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.0% of all adverse event reports for TOCILIZUMAB.

16
Reports of Disseminated cryptococcosis with TOCILIZUMAB
0.0%
of all TOCILIZUMAB reports
8
Deaths
13
Hospitalizations

How Dangerous Is Disseminated cryptococcosis From TOCILIZUMAB?

Of the 16 reports, 8 (50.0%) resulted in death, 13 (81.3%) required hospitalization, and 4 (25.0%) were considered life-threatening.

Is Disseminated cryptococcosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Disseminated cryptococcosis?

PREDNISONE (214) TACROLIMUS (173) MYCOPHENOLATE MOFETIL (167) PREDNISOLONE (122) DEXAMETHASONE (109) METHYLPREDNISOLONE (73) MYCOPHENOLIC ACID (59) AMPHOTERICIN B (51) CYCLOPHOSPHAMIDE (49) CYCLOSPORINE (44)

Which TOCILIZUMAB Alternatives Have Lower Disseminated cryptococcosis Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Disseminated cryptococcosis Reports All Drugs Causing Disseminated cryptococcosis TOCILIZUMAB Demographics